2 results
Approved WMORecruiting
To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues
Approved WMOCompleted
Primary Objective: To assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR/CRhSecondary Objectives:To describe response rate, duration of response, event-freeā¦